Director/PDMR Shareholding
01 November 2024 - 3:00AM
UK Regulatory
Director/PDMR Shareholding
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Notification of Director / PDMR
Dealing
DXS INTERNATIONAL PLC
The Board of DXS International plc (the
“Company” or “DXSP), the AQSE Growth Market quoted clinical
decision support developer and supplier of clinical decision
support systems, has received notification that on 30 October 2024
Mr Bob Sutcliffe, the Chairman, purchased a total of 50,000
Ordinary Shares in the Company at a price of 1.0p per share.
Further, today 31 October 2024, Mr Bob Sutcliffe purchased a total
of 133,333 Ordinary Shares in the Company at a price of 1.5p per
share
Following this transaction Mr Sutcliffe and his
wife’s interest in DXS Ordinary Shares is 1,116,719 Ordinary Shares
representing 1.74% of the issued share capital of the Company.
1
|
Details of the person discharging managerial
responsibilities / person closely associated |
a)
|
Name
|
Mr. Robert Sutcliffe
|
|
2 |
Reason for the notification |
a)
|
Position/status
|
Chairman |
b)
|
Initial notification /Amendment
|
Initial |
3
|
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
|
a)
|
Name
|
DXS INTERNATIONAL PLC |
b)
|
LEI
|
2138001R1KEUWTXEVJ44 |
4
|
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted |
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.33p each |
|
|
|
|
Identification code |
ISIN GB00B2Q6HZ92 |
|
|
|
b)
|
Nature of the transaction
|
Purchase of shares |
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
1.0p |
50,000 |
|
|
|
|
1.5p |
133,333 |
|
d)
|
Aggregated information |
|
|
|
|
|
- Aggregated volume |
|
|
|
|
|
- Price |
|
|
|
|
e)
|
Date of the transaction
|
30 October 2024 and 31 October 2024 |
f)
|
Place of the transaction
|
Aquis Stock Exchange |
The Directors of DXS International plc accept
responsibility for this announcement.
Contacts:
David Immelman
DXS International plc
www.dxs-systems.com
|
01252 719800 |
AQSE Corporate
Broker and Corporate Advisor
Hybridan LLP
Claire Louise Noyce |
020 3764
2341 |
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other
trusted NHS sources, to doctors, nurses and pharmacists in their
workflow and during the patient consultation. This effective
clinical decision support ultimately translates to improved
healthcare outcomes delivered more cost effectively and which
should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
Historical Stock Chart
From Oct 2024 to Nov 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Nov 2023 to Nov 2024
